A new study released by the Centers for Disease Control and Prevention (CDC) points to an alarming exponential increase in kratom-related calls to U.S. poison control centers over the past decade, sparking renewed concerns among federal health officials and potentially signaling a ramp-up in efforts to regulate or even ban specific kratom derivatives nationwide. The report, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), reveals a staggering 1,200% surge in kratom-related reports to the National Poison Data System between 2015 and 2025, from 258 calls to 3,434. This dramatic rise, which included a "marked surge" in 2025 alone, is mirrored by a similar 1,200% increase in reports resulting in adverse events and hospitalizations, climbing from 43 cases in 2015 to 538 in 2025. Over the entire 11-year period covered by the study, a total of 233 kratom-related deaths were recorded, with most fatalities and hospitalizations involving the co-ingestion of other substances such as alcohol, opioids, cannabis, stimulants, and benzodiazepines. Researchers further noted that approximately half of the exposure reports were categorized as "intentional misuse" or suspected suicide attempts, underscoring the complex public health challenges associated with the substance.
Unpacking the CDC’s Findings and Expert Analysis
The recent CDC report provides a granular look at the evolving landscape of kratom use and its associated health risks in the United States. Lead author Christopher Holstege, MD, Professor of Emergency Medicine and Pediatrics at the University of Virginia School of Medicine, emphasized the growing complexity of these cases. "Kratom-related adverse effects are increasing in number and complexity in the United States," Dr. Holstege stated in the report. He attributed this trend to several factors: increasing overall use of kratom, the widespread availability of high-potency kratom products, and the frequent occurrence of multiple-substance exposures, which collectively contribute to hospitalizations stemming from both physical and psychiatric causes. This multifactorial assessment highlights the challenge of isolating kratom’s specific impact when it is often used in conjunction with other compounds.
The study’s findings reinforce concerns previously raised by federal agencies regarding the unregulated nature of kratom products. While kratom has been traditionally used in Southeast Asia for centuries, its relatively recent surge in popularity in the Western world has outpaced scientific research and regulatory frameworks. The leaves of the Mitragyna speciosa tree contain alkaloids such as mitragynine and 7-hydroxymitragynine (7-OH), which interact with opioid receptors in the brain, producing both stimulant-like effects at lower doses and opioid-like analgesic and sedative effects at higher doses. It is this dual action, coupled with claims of pain relief and mood enhancement, that has driven its adoption by millions, particularly those seeking alternatives to conventional pain management or attempting to self-medicate for opioid withdrawal symptoms.
The Role of 7-Hydroxymitragynine (7-OH) in the Surge
A significant element of the CDC’s analysis, and a point of particular interest for regulators, is the increasing prominence of 7-hydroxymitragynine (7-OH). While 7-OH occurs naturally in whole-leaf kratom in trace amounts, the market has seen a rise in vendors selling concentrated versions of this alkaloid. These enhanced 7-OH products significantly boost kratom’s potency as a pain reliever and mood enhancer, leading to more pronounced physiological effects and, consequently, a higher potential for adverse events. The CDC study explicitly attributes the "marked surge" in poison control cases observed in 2025 largely to the growing use of these concentrated 7-OH products.
This distinction between whole-leaf kratom and concentrated 7-OH is crucial and has informed recent actions by the Food and Drug Administration (FDA). Last summer, the FDA indicated its intention to seek classification of 7-OH as an illegal Schedule I controlled substance under the Controlled Substances Act. This move, if successful, would place 7-OH in the same category as drugs like heroin, LSD, and ecstasy, meaning it would be deemed to have a high potential for abuse and no currently accepted medical use. Importantly, the FDA’s proposed action specifically targets 7-OH and not whole-leaf kratom, reflecting a more nuanced approach than previous federal attempts at broader bans. Dr. Holstege underscored the necessity of this distinction for future surveillance and policy: "As FDA moves to regulate 7-hydroxymitragynine but not whole-leaf kratom products, surveillance should distinguish product types to assess risks. Building this evidence base is essential to promoting safe kratom use, identifying high-risk combinations of substances, and guiding public health action to prevent future health effects in this rapidly evolving drug landscape."
Historical Context: Kratom’s Rise and Previous Federal Scrutiny
Kratom’s journey into the American consciousness gained significant momentum during the 2010s, a period marked by escalating restrictions on opioid analgesics. As prescribers became more cautious and patients struggled to access traditional pain relief, many turned to kratom, often marketed as a natural alternative. Estimates suggest that between 5 million and 20 million Americans have used kratom, indicating a substantial user base. This widespread adoption, coupled with a lack of federal regulation, has created a complex environment for public health officials.
This is not the first time federal agencies have attempted to intervene. In 2016, the Drug Enforcement Administration (DEA) and FDA moved to classify both mitragynine and 7-hydroxymitragynine as Schedule I controlled substances, effectively seeking a nationwide ban on kratom. This proposal, also supported by an earlier MMWR study citing an increase in poison control reports, was met with unprecedented public outcry. Advocacy groups, including the American Kratom Association (AKA), mobilized users and researchers, arguing that a ban would strip millions of people of a substance they found beneficial for chronic pain, anxiety, depression, and opioid withdrawal, potentially pushing them back to illicit opioids or other dangerous substances. The DEA ultimately withdrew its proposal, acknowledging a "significant risk of immediate adverse public health consequences" and initiating a public comment period. A top federal health official later made a rare admission, stating that the initial scheduling request was based on "embarrassingly poor evidence & data," highlighting the contentious and often inadequately supported nature of past regulatory attempts.
The Debate Over Poison Control Data: "Notoriously Unreliable"?
Despite the alarming figures presented in the latest CDC report, critics caution against drawing definitive conclusions solely based on poison control center data. Organizations like the American Kratom Association (AKA) have long argued that calls to poison control centers are "notoriously unreliable" as a sole measure of a substance’s risk. They contend that these centers receive calls for a wide range of exposures, many of which involve minor symptoms like upset stomachs or dizziness, and do not necessarily indicate severe toxicity or widespread danger.
Furthermore, critics point to the proportional context. Even using the conservative estimate of 5 million kratom users, the 14,449 kratom-related calls to poison centers over the entire 11-year period represent a tiny fraction—approximately 0.28%—of the estimated user base. This perspective suggests that while adverse events occur, they may not be as pervasive as the raw increase in call volume might initially imply, especially when considering the sheer number of people using the substance.
To illustrate this point, previous research has compared kratom exposure calls to those for other common household items. For example, a study examining poison control data from 2000 to 2017 found that there were more calls related to exposure to nutmeg than there were concerning kratom. While this comparison does not diminish the severity of serious kratom-related incidents, it underscores the need for careful interpretation of poison control statistics and highlights that a high number of calls does not automatically equate to a uniquely dangerous substance when compared to other widely available products. Nevertheless, federal health officials and law enforcement agencies frequently utilize such data to justify changes in the legal status of substances, underscoring its significant influence on policy decisions.
Broader Implications and the Path Forward
The growing controversy surrounding 7-OH and the latest CDC report are undeniably fueling renewed efforts to restrict or ban sales of kratom and its derivatives at both state and local levels. Several states, including Alabama, Arkansas, Indiana, Vermont, and Wisconsin, have already banned kratom, while others have implemented age restrictions or product quality regulations. The federal government’s renewed focus, particularly the FDA’s targeting of 7-OH, suggests that it may only be a matter of time before the DEA re-enters the fray, potentially renewing its efforts to schedule 7-OH, mitragynine, or even whole-leaf kratom itself.
The dilemma for public health authorities remains complex. On one hand, the exponential rise in adverse events and deaths, particularly those linked to concentrated 7-OH products and polysubstance use, signals a clear public health concern. The lack of standardized manufacturing practices, quality control, and accurate labeling in the unregulated kratom market further exacerbates these risks, as consumers may unknowingly ingest contaminated or adulterated products, or products with highly variable alkaloid concentrations.
On the other hand, a broad ban could have significant unintended consequences. Millions of individuals who report therapeutic benefits from kratom, particularly for chronic pain or as a harm reduction tool for opioid withdrawal, could be driven to the black market, where product purity and safety are even less assured. Such a move could also force some back to illicit opioid use, undermining efforts to combat the ongoing opioid crisis.
The call from Dr. Holstege for more nuanced surveillance that distinguishes between different kratom products (e.g., whole-leaf vs. concentrated 7-OH extracts) is critical. This approach could facilitate a more targeted regulatory strategy, allowing authorities to address the highest-risk products while potentially preserving access to less potent forms for those who benefit from them. Such an evidence-based framework would require robust scientific research into kratom’s pharmacology, long-term effects, and potential therapeutic applications, as well as a comprehensive understanding of user demographics and patterns of use.
In this rapidly evolving drug landscape, public health action must balance the imperative to prevent harm with the recognition of individual autonomy and the complex realities of substance use. The latest CDC report serves as a potent reminder of the urgent need for clarity, research, and thoughtful policy development to navigate the challenges and opportunities presented by substances like kratom.